Pfizer monitors brain and liver safety in 1,290 lung cancer patients taking lorbrena
NCT ID NCT03844464
Summary
This study monitored the safety of Lorbrena, a lung cancer drug, in real-world patients after it was approved. It tracked 1,290 patients to understand what factors might lead to brain-related side effects or liver problems, especially when taking Lorbrena with certain other medications. The goal was to gather safety information to help doctors use the drug more safely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
3-22-7, Yoyogi, Shibuya-ku
Tokyo, 151-8589, Japan
Conditions
Explore the condition pages connected to this study.